Diagnostic options · UAE

Genetic tests in Dubai & UAE

Compare available Genetic tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

805

Listed price range

600.00–30,000.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Genetic test prices

Showing 391–405 of 805 matching tests.

Genetic diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-3875 KCNJ1 Gene Bartter Syndrome Type 2 Genetic Test This test analyzes the KCNJ1 gene for mutations associated with Bartter syndrome type 2.	Peripheral Whole Blood (EDTA) or Dried Blood Spot (FTA Card)	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KCNJ1 gene mutations", "Pathogenic variants"] Parameters [] Preparation ["No specific fasting required", "Inform lab of current medications"] Indications ["Suspected Bartter syndrome type 2", "Neonatal salt-wasting nephropathy", "Family history of Bartter syndrome"] Measurement technique Confirm with laboratory Codes LOINC: 69040-7 ICD-10: E26.81 Clinical summary This test analyzes the KCNJ1 gene for mutations associated with Bartter syndrome type 2.
TEST-6181 KCNJ11 Gene Hyperinsulinemic Hypoglycemia Type 2 Genetic Test This genetic test identifies pathogenic variants in the KCNJ11 gene associated with hyperinsulinemic hypoglycemia type 2.	Peripheral whole blood (EDTA)	21–28 calendar days	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KCNJ11 gene"] Parameters [] Preparation ["No fasting required", "Genetic counselling session must be completed prior to scheduling collection", "Inform team of anticoagulant use"] Indications ["Suspected congenital hyperinsulinism", "Neonatal hypoglycaemia", "Family history of hyperinsulinemic hypoglycemia"] Measurement technique Confirm with laboratory Codes LOINC: 48296-0 ICD-10: E16.1 Clinical summary This genetic test identifies pathogenic variants in the KCNJ11 gene associated with hyperinsulinemic hypoglycemia type 2.
TEST-3755 KCNJ5 Gene Hyperaldosteronism Type 3 Genetic Test This NGS-based genetic test detects pathogenic variants in the KCNJ5 gene causative of familial hyperaldosteronism type III (FH-III). It enables precision diagnosis and targeted ma...	Whole blood (EDTA, 3–5 mL), FTA card dried blood spot, or extracted genomic DNA (≥1 µg)	21–28 Days (3–4 Weeks) from sample receipt	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KCNJ5 gene", "Single-nucleotide variants (SNVs)", "Small insertions and deletions (indels)"] Parameters [] Preparation ["Consult referring physician regarding medication adjustments (antihypertensives, potassium-modifying drugs)", "Provide complete clinical history, biochemical results (aldosterone, renin, potassium), and imaging reports", "Pre-test genetic counselling recommended to construct a detailed family pedigree"] Indications ["Suspicion of Familial Hyperaldosteronism Type III (FH-III)", "Early-onset hypertension with hypokalemia", "Family history suggestive of FH-III", "Need for genetic subtyping of primary aldosteronism"] Measurement technique Confirm with laboratory Codes LOINC: 94802-9 ICD-10: E26.09 Clinical summary This NGS-based genetic test detects pathogenic variants in the KCNJ5 gene causative of familial hyperaldosteronism type III (FH-III). It enables precision diagnosis and targeted management of early-onset hypertension and electrolyte dysregulation.
TEST-4433 KCNMA1 Gene Epilepsy & Paroxysmal Dyskinesia Genetic Test This genetic test evaluates the KCNMA1 gene for pathogenic variants associated with epilepsy and paroxysmal dyskinesia.	Peripheral Whole Blood (EDTA)	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KCNMA1 gene"] Parameters [] Preparation [] Indications ["Diagnosis of KCNMA1-related epilepsy-paroxysmal dyskinesia syndrome", "Evaluation of patients with unexplained epilepsy or movement disorders"] Measurement technique Confirm with laboratory Codes LOINC: 51955-5 ICD-10: G40.89, G24.8 Clinical summary This genetic test evaluates the KCNMA1 gene for pathogenic variants associated with epilepsy and paroxysmal dyskinesia.
TEST-4117 KCNQ1 Gene Short QT Syndrome Type 2 Genetic Test This genetic test evaluates the KCNQ1 gene for pathogenic variants associated with Short QT Syndrome Type 2.	Whole blood, extracted DNA, or FTA card (peripheral blood)	3–4 weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KCNQ1 gene", "Cardiac channelopathy risk"] Parameters [] Preparation ["No fasting required", "No medication changes required"] Indications ["Suspected Short QT Syndrome Type 2", "Family history of inherited arrhythmia syndromes", "Evaluation of unexplained syncope or sudden cardiac death"] Measurement technique Confirm with laboratory Codes LOINC: 21636-6 ICD-10: I45.8, Z13.6 Clinical summary This genetic test evaluates the KCNQ1 gene for pathogenic variants associated with Short QT Syndrome Type 2.
TEST-5546 KCTD7 Gene Genetic Test for Progressive Myoclonus Epilepsy Type 3 (EPM3) This test detects pathogenic variants in the KCTD7 gene to confirm a diagnosis of Progressive Myoclonus Epilepsy Type 3 (EPM3).	Whole Blood (EDTA tube), Extracted DNA (≥1µg, A260/280 1.8‑2.0), or FTA Card	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KCTD7 gene", "Copy number variations (CNV) in the KCTD7 gene"] Parameters [] Preparation ["No fasting required", "Inform phlebotomist of all current medications and supplements", "Do not discontinue prescribed anti-epileptic medication without neurologist instruction"] Indications ["Individuals presenting with clinical features suggestive of progressive myoclonic epilepsy", "Distinguishing EPM3 from other progressive myoclonic epilepsies", "Informed reproductive risk assessment"] Measurement technique Confirm with laboratory Codes LOINC: 42629-7 ICD-10: G40.3 Clinical summary This test detects pathogenic variants in the KCTD7 gene to confirm a diagnosis of Progressive Myoclonus Epilepsy Type 3 (EPM3).
TEST-2050 KDR Gene Hemangioma Susceptibility Genetic Test This test evaluates the KDR gene for variants associated with an increased risk of developing familial infantile capillary hemangioma.	Peripheral Whole Blood or DNA FTA Card	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KDR (VEGFR2) gene variants", "Germline mutations", "CNVs"] Parameters [] Preparation ["No specific fasting required", "No medication adjustments needed"] Indications ["Genetic risk assessment for familial infantile capillary hemangioma", "Early surveillance for at-risk infants"] Measurement technique Confirm with laboratory Codes LOINC: 55233-1 ICD-10: Z15.89, D18.00 Clinical summary This test evaluates the KDR gene for variants associated with an increased risk of developing familial infantile capillary hemangioma.
TEST-3412 KHDC3L Gene Sequencing for Recurrent Hydatidiform Mole (Type 2) Test This test evaluates the KHDC3L gene for pathogenic variants linked to recurrent hydatidiform mole type 2.	Peripheral Whole Blood (EDTA), Extracted DNA, or FTA Card	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KHDC3L gene", "Genetic predisposition to recurrent hydatidiform mole type 2"] Parameters [] Preparation ["No fasting required", "No special preparation needed"] Indications ["Recurrent hydatidiform mole", "Family history of hydatidiform mole", "Genetic counseling for reproductive planning"] Measurement technique Confirm with laboratory Codes LOINC: 82978-8 ICD-10: O01.9 Clinical summary This test evaluates the KHDC3L gene for pathogenic variants linked to recurrent hydatidiform mole type 2.
TEST-2578 KIF11 Gene Microcephaly with or without Chorioretinopathy, Lymphedema, or Mental Retardation (MCLMR) Genetic Test This test detects pathogenic variants within the KIF11 gene associated with Microcephaly with or without Chorioretinopathy, Lymphedema, or Mental Retardation (MCLMR).	Peripheral whole blood (2-3 mL EDTA) or dry blood spot (FTA card)	3-4 weeks from sample receipt	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KIF11 gene"] Parameters [] Preparation [] Indications ["Suspected diagnosis of MCLMR syndrome", "Family history of MCLMR syndrome"] Measurement technique Confirm with laboratory Codes LOINC: 81421-7 ICD-10: Q02 Clinical summary This test detects pathogenic variants within the KIF11 gene associated with Microcephaly with or without Chorioretinopathy, Lymphedema, or Mental Retardation (MCLMR).
TEST-5337 KIF2A Gene Neurodevelopmental Malformation and Microcephaly Genetic Test This genetic test evaluates the KIF2A gene for pathogenic variants associated with neurodevelopmental malformations and microcephaly.	Whole Blood (EDTA) or Buccal Swab (FTA Card)	3 to 4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KIF2A gene", "Single nucleotide variants", "Small insertions/deletions", "Structural rearrangements"] Parameters [] Preparation ["No specific fasting required", "Inform lab of any recent blood transfusions"] Indications ["Unexplained neurodevelopmental delay", "Microcephaly", "Suspected KIF2A-related disorder"] Measurement technique Confirm with laboratory Codes LOINC: 93327-5 ICD-10: Q02 Clinical summary This genetic test evaluates the KIF2A gene for pathogenic variants associated with neurodevelopmental malformations and microcephaly.
TEST-5719 KIF5A Gene SPG10 Genetic Test This test identifies pathogenic variants in the KIF5A gene associated with autosomal dominant hereditary spastic paraplegia type 10 (SPG10).	Peripheral Whole Blood	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KIF5A gene", "Axonal transport disruption"] Parameters [] Preparation ["No specific fasting required", "No medication or diet restrictions"] Indications ["Individuals with progressive lower limb spasticity", "Family history of hereditary spastic paraplegia", "Unexplained gait disturbances", "Pre-conception carrier screening for SPG10", "Referral from a neurologist or genetic counselor"] Measurement technique Confirm with laboratory Codes LOINC: 95035-4 ICD-10: G11.4 Clinical summary This test identifies pathogenic variants in the KIF5A gene associated with autosomal dominant hereditary spastic paraplegia type 10 (SPG10).
TEST-3729 KISS1R Gene Hypogonadotropic Hypogonadism Genetic Test This genetic test detects pathogenic variants in the KISS1R gene associated with congenital hypogonadotropic hypogonadism.	Peripheral blood or FTA card (dried blood spot)	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KISS1R gene sequence", "Pathogenic variants", "Copy number variants"] Parameters [] Preparation ["No fasting required", "No specific medication or diet restrictions"] Indications ["Suspected congenital hypogonadotropic hypogonadism", "Evaluation of infertility", "Family history of CHH"] Measurement technique Confirm with laboratory Codes LOINC: 81247-9 ICD-10: E23.0 Clinical summary This genetic test detects pathogenic variants in the KISS1R gene associated with congenital hypogonadotropic hypogonadism.
TEST-4779 KLF8 Gene Non-Syndromic Intellectual Disability Genetic Test This genetic test evaluates the KLF8 gene for pathogenic variants associated with non-syndromic intellectual disability.	Whole Blood (EDTA), Dried Blood Spot (FTA Card), or High-Quality Extracted Genomic DNA	21–28 Working Days	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KLF8 gene", "Coding Exons", "Splice Junctions", "UTR Regions"] Parameters [{"name": "Precision", "reference_range": ">99.9% Single-Nucleotide Resolution (NGS)"}, {"name": "Methodology", "reference_range": "Next Generation Sequencing (NGS) — High-Throughput Parallel Sequencing"}, {"name": "Coverage", "reference_range": "Full Gene: Coding Exons, Splice Junctions, UTR Regions"}, {"name": "Clinical Reporting", "reference_range": "ACMG/AMP Guidelines (Latest Version) + Clinical Correlation Note"}] Preparation ["Pre-test genetic counselling is mandatory", "A three-generation pedigree chart is mandatory"] Indications ["Individuals with unexplained global developmental delay or moderate-to-severe intellectual disability without dysmorphic features", "Carrier screening in consanguineous families"] Measurement technique Confirm with laboratory Codes LOINC: 48018-3 ICD-10: F79 Clinical summary This genetic test evaluates the KLF8 gene for pathogenic variants associated with non-syndromic intellectual disability.
TEST-4007 KLHL3 Gene Pseudohypoaldosteronism Type 2D Genetic Test This genetic test analyzes the KLHL3 gene to identify variants associated with Pseudohypoaldosteronism Type 2D, a form of monogenic hypertension.	Peripheral whole blood (EDTA)	3 – 4 weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KLHL3 gene sequence", "Copy Number Variations (CNVs) in KLHL3"] Parameters [] Preparation [] Indications ["Diagnosis of Pseudohypoaldosteronism Type 2D", "Guiding thiazide diuretic therapy", "Screening at-risk family members"] Measurement technique Confirm with laboratory Codes LOINC: 94219-0 ICD-10: E27.4 Clinical summary This genetic test analyzes the KLHL3 gene to identify variants associated with Pseudohypoaldosteronism Type 2D, a form of monogenic hypertension.
TEST-5444 KLK4 Gene Amelogenesis Imperfecta Type 2A1 Genetic Test This genetic test identifies pathogenic variants in the KLK4 gene associated with autosomal recessive Amelogenesis Imperfecta Type 2A1.	Whole Blood (FTA Card or Venipuncture)	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KLK4 gene sequence", "Pathogenic variants (SNVs, indels)"] Parameters [] Preparation [] Indications ["Suspected Amelogenesis Imperfecta Type 2A1", "Family history of enamel defects"] Measurement technique Confirm with laboratory Codes LOINC: 77634-5 ICD-10: K00.5, Z13.71, Z82.79 Clinical summary This genetic test identifies pathogenic variants in the KLK4 gene associated with autosomal recessive Amelogenesis Imperfecta Type 2A1.

Category overview

Genetic: overview

Unlocking the blueprint of your DNA provides profound, proactive insights into your family’s future and personal health risks. Integrated within our advanced Biochemistry and molecular services, specialized Genetic testing evaluates inherited traits, metabolic predispositions, and carrier statuses. Utilizing cutting-edge diagnostic technology, comprehensive genetic screening offers the vital clarity needed to safely guide tailored medical strategies and family planning. As an undisputed leader in innovation among diagnostic labs in Dubai and the UAE, DNA Labs guarantees the highest standards of strict patient confidentiality, unparalleled diagnostic precision, and rapid reporting. Empower your health decisions with certainty—book your genetic testing in UAE, coordinate a secure sample collection, or connect with our specialized genetics team today.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.